Characteristics of RA patients
| Gender/age | Disease duration (years) | Swollen/tender joint count | DAS28 | ESR (mm/h) | CRP (mg/l) | RF (IU/ml)* | ACPA (OD)† | NSAID/GLC‡ | DMARD/biotherapy§ | Stimulation by immune complexes¶ |
|---|---|---|---|---|---|---|---|---|---|---|
| F/71 | 24 | 1/5 | 5 | 45 | 3 | 273 | 1.24 | +/− | MTX/INF | Mc |
| F/49 | 18 | 1/1 | 4.3 | 9 | 1 | 50 | 0.09 | −/− | MTX/INF | Mc |
| M/64 | 19 | 2/2 | 3.6 | 11 | 11 | 234 | 1.09 | −/− | MTX/− | Mc |
| M/70 | 20 | 1/4 | 4.8 | 70 | 56 | 428 | 0.97 | −/− | MTX/ETA | Mac |
| F/42 | 8 | 12/20 | 7.3 | 55 | 38 | 141 | 0.91 | +/− | LEF/− | Mac |
| F/72 | 14 | 0/2 | 5.6 | 20 | 4 | ND | 0 | −/− | PEN/− | Mac |
| F/80 | 24 | 0/10 | 5.0 | 54 | 21 | 6 | 0 | −/+ | LEF/− | Mac |
| M/67 | 23 | 13/12 | 7.0 | 123 | 49 | 241 | 0.71 | −/− | LEF/− | Mac |
| M/55 | 1 | 1/2 | 3.3 | 14 | 63 | 186 | 1.29 | −/+ | MTX/− | Mc/Mac |
| M/45 | 15 | 3/3 | 4.4 | 36 | 1 | 188 | 2.49 | +/− | MTX/INF | Mc/Mac |
| M/58 | 9 | 16/8 | 6.8 | 59 | 131 | 194 | 0.96 | +/− | LEF/INF | Mc/Mac |
| F/46 | 20 | 4/19 | 7.0 | 89 | 79 | 203 | 2.50 | +/+ | PEN/− | Mc/Mac |
| F/70 | 13 | 0/2 | 4.3 | 48 | 42 | 79 | 2.09 | −/+ | CYC/− | Mc/Mac |
| F/67 | 21 | 2/18 | 6.0 | 56 | 19 | 127 | 0.79 | −/− | MTX/INF | Mc/Mac |
| M/82 | 14 | 8/0 | 2.6 | 13 | 2 | 53 | 0.26 | −/− | MTX/INF | Mc/Mac |
| M/57 | 12 | 5/0 | 3.3 | 19 | 29 | 98 | 1.42 | +/− | LEF/INF | Mc/Mac |
| F/62 | 33 | 0/0 | 1.7 | 10 | 5 | 169 | 0.52 | −/− | MTX/INF | Mc/Mac |
| F/71 | 8 | 11/3 | 5.9 | 51 | 37 | 512 | 0.50 | −/+ | −/− | Mc/Mac |
| F/74 | 16 | 0/0 | 2.8 | 30 | 16 | 62 | 0.01 | +/− | MTX/INF | Mc/Mac |
| F/55 | 19 | 2/3 | 4 | 28 | 3 | 328 | 0.91 | −/+ | −/− | Mc/Mac |
| F/66 | 43 | 2/9 | 5.8 | 52 | 84 | 98 | 1.26 | +/− | −/− | Mc/Mac |
| F/50 | 16 | 0/2 | 3.2 | 21 | 0 | 9 | 0 | −/− | MTX/INF | Mc/Mac |
| F/50 | 19 | 9/7 | 6.6 | 64 | 66 | ND | 1.43 | +/− | −/ADA | Mc/Mac |
| F/83 | 32 | 2/5 | 5 | 23 | 4 | 162 | 0 | −/+ | −/ETA | Mc/Mac |
| F/33 | 6 | 0/0 | 2.1 | 16 | 4 | 172 | 0.84 | +/+ | MTX/INF | Mc/Mac |
| M/70 | 1 | 0/0 | 2.8 | 28 | 18 | 25 | 0 | −/+ | MTX/− | Mc/Mac |
| F/81 | 26 | 0/0 | 1.9 | 14 | 0.5 | 221 | 0.19 | −/+ | LEF/− | Mc/Mac |
| M/72 | 26 | 0/0 | 3.0 | 41 | 32 | 414 | 2.66 | −/+ | PEN/ABA | Mc/Mac |
| M/61 | 13 | 0/2 | 3.8 | 23 | 10 | 274 | 1.51 | +/− | MTX/ABA | Mc/Mac |
| F/59 | 35 | 0/14 | 6.0 | 56 | 88 | 189 | 1.96 | −/+ | −/− | ND |
| M/58 | 13 | 4/3 | 5.4 | 94 | 159 | 70 | 0.14 | −/+ | MTX/ETA | ND |
| F/66 | 7 | 0/0 | 3.5 | 31 | 18 | 2 | 0 | +/− | LEF/− | ND |
| M/41 | 1 | 4/2 | 4 | 27 | 26 | 95 | 1.57 | +/− | −/− | ND |
| F/79 | 30 | 1/0 | 3.3 | 14 | 14 | 75 | 0.80 | −/+ | −/− | ND |
↵* Rheumatoid factor (RF) was detected by flow cytometric quantification of IgM binding on fluorescent dyed microspheres coated with human IgG Fc fragments (FIDIS Rheumatoid Assay; Biomedical Diagnostics, Marne la Vallée, France) performed at the Immunology Laboratory, Rangueil Hospital, Toulouse, France (positivity cut-off 25 IU/ml).
↵† Anti-citrullinated proteins auto antibodies (ACPA) titres were determined by ELISA on citrullinated human fibrinogen (C-FBG) and the sera were classified according to a previously defined positivity threshold corresponding to a 98.5% diagnostic specificity (optical density ≥0.12).51
↵‡ Indicates the presence (+) or absence (−) of a non-steroidal anti-inflammatory drug (NSAID) and of a glucocorticoid (GLC) in the undergone treatment.
↵§ Indicates the disease-modifying antirheumatic drug (DMARD) and biotherapy used: methotrexate (MTX), leflunomide (LEF), penicillamine (PEN), cyclophosphamide (CYC) or no DMARD (−), on the one hand, and infliximab (INF), etanercept (ETA), adalimumab (ADA), abatacept (ABA) or no biotherapy (−), on the other hand.
↵¶ Indicates that stimulation by ACPA-containing immune complexes could be tested in monocytes (Mc), macrophages (Mac) or both monocytes and macrophages (Mc/Mac) or could not be done (ND).
CRP, C-reactive protein; DAS, disease activity score; ESR, erythrocyte sedimentation rate; RA, rheumatoid arthritis.